John D. Quisel Sells 5,200 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CEO John D. Quisel sold 5,200 shares of the firm's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $55.09, for a total value of $286,468.00. Following the transaction, the chief executive officer owned 161,828 shares of the company's stock, valued at approximately $8,915,104.52. The trade was a 3.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Disc Medicine Trading Down 0.8%

Shares of NASDAQ:IRON traded down $0.41 during trading on Tuesday, reaching $52.97. The stock had a trading volume of 163,376 shares, compared to its average volume of 338,714. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average price of $49.49 and a 200-day moving average price of $51.86. The stock has a market cap of $1.83 billion, a P/E ratio of -13.51 and a beta of 0.76.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a report on Thursday, July 3rd. Wedbush reaffirmed an "outperform" rating and set a $90.00 price objective on shares of Disc Medicine in a research note on Monday, June 16th. Morgan Stanley started coverage on shares of Disc Medicine in a research report on Thursday, July 3rd. They set an "overweight" rating and a $85.00 price objective for the company. BMO Capital Markets boosted their price objective on Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a research report on Monday, May 12th. Finally, Cantor Fitzgerald raised their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Disc Medicine currently has a consensus rating of "Buy" and an average price target of $96.70.

Hedge Funds Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Disc Medicine by 8.2% during the fourth quarter. Bank of New York Mellon Corp now owns 57,261 shares of the company's stock worth $3,630,000 after purchasing an additional 4,356 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Disc Medicine by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 165,072 shares of the company's stock valued at $10,466,000 after purchasing an additional 4,518 shares during the period. Victory Capital Management Inc. increased its position in Disc Medicine by 7.4% during the fourth quarter. Victory Capital Management Inc. now owns 236,244 shares of the company's stock worth $14,978,000 after acquiring an additional 16,230 shares during the period. Raymond James Financial Inc. bought a new position in Disc Medicine during the fourth quarter worth $5,579,000. Finally, Intech Investment Management LLC increased its holdings in Disc Medicine by 69.8% in the 4th quarter. Intech Investment Management LLC now owns 7,890 shares of the company's stock valued at $500,000 after buying an additional 3,243 shares during the period. Institutional investors and hedge funds own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.